Premium
Delayed introduction of G‐CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high‐risk malignancies: Retrospective study of 45 cases
Author(s) -
Dolgopolov Igor,
Andreeva Ludmila,
Yankelevich Maxim,
Mscheidze Demur,
Siegel Stuart,
Mentkevich George
Publication year - 2003
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.10371
Subject(s) - leukapheresis , medicine , filgrastim , chemotherapy , granulocyte colony stimulating factor , surgery , transplantation , gastroenterology , cd34 , stem cell , genetics , biology
Abstract We retrospectively compared the effects of two time points of G‐CSF (Filgrastim) introduction for PBSC mobilization in 45 children with different malignancies. Seventeen patients received the first G‐CSF dose on day 2 or 3 following chemotherapy (group 1). Twenty‐eight patients received a “flexible” G‐CSF injection schedule when the G‐GSF was started at the time of the first platelet count rise during post‐chemotherapy recovery phase (group 2). Leukapheresis was performed when WBC recovery reached >2.0 × 10 9 /l or if the peripheral blood CD34 + cell level was >0.01 × 10 9 /l. A median of 2 (1–4) leukapheresis procedures was performed in both groups to yield a median of 4.2 and 6.1 × 10 6 CD34 + cells/kg in groups 1 and 2, respectively, which was generally sufficient for auto‐transplantation. The proportion of patients with a failure of PBSC collection was similar and G‐CSF consumption estimated through the total cycle dose was 2.3 times less in group 2 without increasing infectious risks. The short‐term hematological recovery and the early post‐transplant course were similar in the two groups. Delayed introduction of G‐CSF after chemotherapy allowed PBSC harvest equivalent to that obtained after early G‐CSF introduction. This approach could be an interesting alternative in PBSC mobilization but should be assessed by a prospective controlled study. Am. J. Hematol. 73:225–229, 2003. © 2003 Wiley‐Liss, Inc.